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Summary  
 Hyperphosphorylation of microtubule-associated protein tau is a pathological hallmark 
of Alzheimer’s disease (AD). Glycogen synthase kinase 3β (GSK3β) is a major protein kinase 
contributing the hyperphosphorylation. However, it is not known how GSK3β target tau in AD 
brain. GSK3β is a multifunctional Ser/Thr protein kinase, which is thought to be constitutively 
activate in cells by autophosphorylation at Tyr216 and inactivated by phosphorylation at Ser9 
with Akt downstream of insulin signaling.  The GSK3β activity has previously been evaluated 
by immunoblotting of inhibitory Ser9 phosphorylation (pS9), but this assay does not necessarily 
measure the kinase activity itself. To understand the pathological hyperphosphorylation of tau in 
AD, it is critical to know the regulation mechanism of GSK3β activity in vivo. As described 
above, there has been a big problem in the GSK3β research, no proper method to measure 
GSK3β activity in cells and tissues. In this thesis, I developed the method measuring the GSK3β 
activity in vivo using the Phos-tag SDS-PAGE technique. 
 There were three phosphoisotypes in GSK3β when GSK3β was expressed in cells; 
double phosphorylation at Ser9 and Tyr216, single phosphorylation at Tyr216 and the 
nonphosphorylated isotype. I confirmed that Tyr216 phosphorylated GSK3β is active and 
Tyr216 phosphorylation was required for further phosphorylation at Ser9. These 
phosphoisotypes were separated in Phos-tag SDS-PAGE. They were detected by immunoblots 
with single anti- GSK3β antibody and quantified by densitometric scanning. The active GSK3β 
account for the majority in cells and brains. Although levels of phospho-Ser9 were in fact 
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increased by insulin treatment of cells, the increase was only a minor fraction of GSK3β and the 
total active GSK3β remained unchanged.  In mouse brains too, GSK3β was principally in the 
active form with little Ser9 phosphorylation, and the phosphoisotypes of GSK3β changed 
depending on the regions of the brain, age and sex. These results indicate that the Phos-tag 
SDS-PAGE method provides a simple and appropriate measurement of active GSK3β in vivo, 
and the activity may be regulated by the mechanism other than phosphorylation on Ser9. 
 
 
 
 
 
 
 
 
 
 
